Four Leaf Rover Seven Shrooms: Product Profile

Four Leaf Rover Seven Shrooms is a named branded product for Dogs; manufacturer positioning must be kept separate from independent clinical evidence.

Oral mushroom-extract powder mixed with food. Intended species: Dogs.

Organic extracts of Turkey Tail, Chaga, Cordyceps, Phellinus, Maitake, Reishi, and Shiitake. The 2024 official product guide lists 243 mg of each extract per teaspoon and no inactive ingredients. The current product page describes whole fruiting bodies, organic cultivation, and batch testing for beta-glucans.

The manufacturer presents Seven Shrooms as a veterinarian-formulated, seven-mushroom blend for balanced immune response, organ function, and general wellness. Those are wellness positioning statements and do not establish prevention, treatment, or control of a canine tumor.

May be discussed only as adjunctive/supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive goal, objective review date, adverse-effect plan, and stopping rule with the veterinarian.

Bring the current label, lot, complete ingredient panel, seller and country version, and every medicine and supplement to the treating veterinarian.

No controlled veterinary oncology trial of the finished Seven Shrooms blend was identified in the current official material. Evidence regarding one species, one purified polysaccharide, or a different extract cannot demonstrate the clinical effect of this seven-ingredient combination. Product testing for beta-glucans addresses composition and quality, not tumor shrinkage, recurrence, progression, or survival.

Seven mushroom species broaden the potential for allergy, gastrointestinal intolerance, batch or extraction differences, and interactions. Discuss autoimmune disease, immunosuppressive therapy, immunotherapy, anticoagulants, surgery, pregnancy, liver or kidney disease, and all duplicate mushrooms or antioxidants. Obtain current label and lot information and do not derive a cancer dose from ingredient research.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

Marketed in the United States as an animal supplement, not identified as an FDA-approved animal drug. Organic, veterinarian-formulated, NASC, or third-party-tested statements do not establish cancer-treatment approval or efficacy.

United States; International online market

Agree on a modest supportive goal and review date. Record appetite, vomiting, diarrhea, stool, itching, swelling, activity, weight, and medication adherence. If signs change, assess disease, treatment toxicity, diet, infection, and the supplement rather than assuming one cause. Continue oncology-directed imaging, pathology, and laboratory monitoring.